About Interleukin Genetics (OTCMKTS:ILIU)
Interleukin Genetics, Inc. develops and markets genetic tests for chronic diseases and health-related conditions. The Company operates through the genetic test business segment. The Company's products include PerioPredict genetic test and Inherent Health line of genetic tests. PerioPredict is a genetic risk test that analyzes genetic variations associated with inflammation and identifies individuals with a life-long predisposition to over-produce inflammation. PerioPredict identifies specific polymorphisms (genetic variations) in genes that regulate the production of interleukin-1 cytokines. PerioPredict identifies adults at increased risk for severe periodontal disease. The Company markets additional genetic tests through its Inherent Heath brand. Its additional genetic tests include weight management genetic test, bone health genetic test, heart health genetic test, nutritional needs genetic test and wellness select genetic test.
Industry, Sector and Symbol
Trailing P/E Ratio-0.1125
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$2.51 million
Price / Sales0.41
Price / CashN/A
Book Value($0.01) per share
Price / Book-0.45
Return on EquityN/A
Return on Assets-353.70%
Interleukin Genetics (OTCMKTS:ILIU) Frequently Asked Questions
What is Interleukin Genetics' stock symbol?
Interleukin Genetics trades on the OTCMKTS under the ticker symbol "ILIU."
How were Interleukin Genetics' earnings last quarter?
Interleukin Genetics, Inc (OTCMKTS:ILIU) announced its quarterly earnings data on Friday, May, 12th. The company reported ($0.01) EPS for the quarter. The business earned $0.20 million during the quarter. View Interleukin Genetics' Earnings History.
Who are some of Interleukin Genetics' key competitors?
Some companies that are related to Interleukin Genetics include Atlas Energy Group (ATLS), LDK Solar (LDKYQ), Sabine Oil & Gas (SOGCQ), FunctionX (FNCX), OmniTek Engineering (OMTK), Republic Airways (RJETQ), Cardinal Energy Group (CEGX), KiOR (KIORQ), Inventergy Global (INVT), Towerstream (TWER), Horsehead (ZINCQ), Excel Maritime Carriers (EXMCQ), Alpha Natural Resources (ANRZQ), Digiliti Money Group (DGLT), Blue Ridge Mountain Resources (MHRCQ), GSE (GSEH), Affymax (AFFY) and Atlas Resource Partners (ARPJQ).
Who are Interleukin Genetics' key executives?
Interleukin Genetics' management team includes the folowing people:
- Barry Kallander, President, Treasurer, Secretary, Director
- Stephan Toutain, Chief Commercial Officer (Age 50)
- Dayton C. Misfeldt, Independent Director (Age 43)
How do I buy Interleukin Genetics stock?
Shares of Interleukin Genetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Interleukin Genetics' stock price today?
One share of Interleukin Genetics stock can currently be purchased for approximately $0.00.
How big of a company is Interleukin Genetics?
Interleukin Genetics has a market capitalization of $1.03 million and generates $2.51 million in revenue each year. The company earns $-7,410,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis.
How can I contact Interleukin Genetics?
Interleukin Genetics' mailing address is 135 Beaver St, WALTHAM, MA 02452-8412, United States. The company can be reached via phone at +1-781-3980700 or via email at [email protected]
MarketBeat Community Rating for Interleukin Genetics (ILIU)MarketBeat's community ratings are surveys of what our community members think about Interleukin Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Interleukin Genetics (OTCMKTS:ILIU) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Interleukin Genetics (OTCMKTS:ILIU) Earnings History and Estimates Chart
Interleukin Genetics (OTCMKTS ILIU) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/12/2017||Q1 2017||($0.01)||$0.20 million||View||N/A|
|11/15/2016||Q3 2016||($0.01)||$0.73 million||View||N/A|
|8/15/2016||Q2||($0.01)||($0.01)||$0.25 million||$0.59 million||View||Listen|
|5/12/2016||Q1||($0.01)||($0.01)||$0.27 million||$0.96 million||View||Listen|
|3/17/2016||Q4||($0.01)||($0.01)||$0.31 million||$0.37 million||View||Listen|
|11/12/2015||Q3||($0.01)||($0.01)||$0.36 million||$0.30 million||View||N/A|
|8/14/2015||Q2||($0.01)||($0.01)||$0.37 million||$0.38 million||View||Listen|
|3/20/2015||Q4 2014||($0.01)||($0.01)||$0.52 million||$0.32 million||View||N/A|
|11/14/2014||Q3 2014||($0.01)||($0.01)||$0.58 million||$0.47 million||View||N/A|
|8/13/2014||Q2 2014||($0.01)||($0.01)||$0.47 million||$0.53 million||View||N/A|
|3/20/2014||Q4 13||($0.01)||($0.02)||$0.54 million||$0.67 million||View||N/A|
Interleukin Genetics (OTCMKTS:ILIU) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Interleukin Genetics (OTCMKTS:ILIU)
No dividend announcements for this company have been tracked by MarketBeat.com
Interleukin Genetics (OTCMKTS ILIU) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 54.40%
Institutional Ownership Percentage: 0.53%
Interleukin Genetics (OTCMKTS ILIU) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|7/29/2016||Bay City Capital Fund V, L.P.||Major Shareholder||Buy||30,181,086||$0.10||$3,018,108.60|| |
|7/29/2016||Kenneth S. Kornman||Insider||Buy||25,150||$0.10||$2,515.00|| |
|7/29/2016||Stephen J Dipalma||CFO||Buy||100,603||$0.10||$10,060.30||349,855|| |
|12/23/2014||Bay City Capital Llc||Major Shareholder||Buy||26,491,952||$0.10||$2,649,195.20|| |
|12/23/2014||Stephen J Dipalma||CFO||Buy||249,252||$0.10||$24,925.20|| |
Interleukin Genetics (OTCMKTS ILIU) News Headlines
Interleukin Genetics (OTCMKTS:ILIU) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Interleukin Genetics (OTCMKTS:ILIU) Income Statement, Balance Sheet and Cash Flow Statement
Interleukin Genetics (OTCMKTS ILIU) Stock Chart for Friday, January, 19, 2018